Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

NCT07033481

Status	RECRUITING
Phase	Phase 2
Sponsor	EIP Pharma Inc
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (15)

- Men and women aged 40-85 years at Screening.
- Participant or participant's legally authorized representative (where applicable) is willing and able to provide written informed consent.
- Clinical diagnosis of nfvPPA by consensus criteria \[Gorno-Tempini et al, 2011\].
- At least one of the following core features must be present:
- Agrammatism in language production

... and 10 more (see full listing online)

Exclusion (22)

- Brain Magnetic Resonance Image (MRI) incompatible with a diagnosis of nfvPPA.
- History or evidence of a central nervous system (CNS) condition other than nfvPPA which may cause symptoms of aphasia or dementia, including but not limited to Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), inflammatory/demyelinating CNS conditions, Creutzfeldt Jakob disease, vascular dementia, post-stroke dementia, etc.
- Features or Parkinsonism, corticobasal syndrome or progressive supranuclear palsy that are as or more prominent than the language features of nfvPPA, and/or motor features which are sufficiently severe that they could significantly impact performance on any of the clinical or neuropsychological measures.
- Plasma pTau217 result with a high likelihood of the presence of amyloid pathology at Screening or documented evidence of positive biomarkers associated with Alzheimer's disease pathology (e.g., abnormal plasma A²42/40ratio, abnormal CSF phospo-tau/amyloid ratio, or presence of amyloid tracer update on brain amyloid positron emission tomography \[PET\] imaging).
- Known progranulin (GRN) mutations.

... and 17 more (see full listing online)

Locations (3 total)

Mayo Clinic, Rochester, Minnesota, United States
The Ohio State University, Columbus, Ohio, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States